analyst
NASDAQ · BNTX
BioNTech SE
Healthcare · Biotechnology
$96.69
Down-$2.17 (-2.20%)
Updated Sep 16, 2026, 10:00 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 23.08B
- P/E ratio
- -57.03
- Dividend yield
- 0.00%
- 52-week range
- $79.52 – $120.33
- Volume
- 590.9K
- Avg. volume
- 1.03M
Price performance
BNTX price history
1M range · 20 trading sessions · Daily adjusted prices
BNTX closed at $96.69 after 20 trading sessions, up 4.25% for the selected period.
- Last close
- $96.69
- Period change
- +4.25%
- Period low
- $92.75
- Period high
- $116.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $97.04 | $97.66 | $95.80 | $96.69 | 590.9K |
| Sep 14, 2026 | $102.01 | $103.00 | $97.95 | $98.86 | 1.22M |
| Sep 11, 2026 | $96.77 | $97.90 | $96.00 | $96.73 | 1.18M |
| Sep 10, 2026 | $97.50 | $97.50 | $95.85 | $96.40 | 773.74K |
| Sep 9, 2026 | $98.50 | $98.635 | $96.87 | $98.13 | 707.3K |
| Sep 8, 2026 | $100.24 | $101.33 | $98.18 | $98.66 | 1.13M |
| Sep 4, 2026 | $102.78 | $104.82 | $102.325 | $103.76 | 626.06K |
| Sep 3, 2026 | $104.55 | $105.15 | $102.25 | $102.88 | 1.18M |
| Sep 2, 2026 | $103.24 | $105.4571 | $102.51 | $103.81 | 753.65K |
| Sep 1, 2026 | $100.98 | $102.14 | $100.295 | $101.945 | 1.04M |
| Aug 31, 2026 | $102.01 | $103.00 | $100.8391 | $101.61 | 1.09M |
| Aug 28, 2026 | $102.34 | $105.23 | $98.80 | $102.075 | 3.07M |
| Aug 27, 2026 | $111.69 | $112.81 | $110.25 | $111.40 | 1.55M |
| Aug 26, 2026 | $112.91 | $113.97 | $111.215 | $112.56 | 1.26M |
| Aug 25, 2026 | $113.88 | $116.87 | $113.405 | $114.05 | 1.36M |
| Aug 24, 2026 | $114.03 | $114.195 | $110.517 | $112.82 | 1.85M |
| Aug 21, 2026 | $110.92 | $120.33 | $110.89 | $116.57 | 2.96M |
| Aug 20, 2026 | $109.06 | $112.39 | $106.38 | $110.89 | 3.53M |
| Aug 19, 2026 | $109.29 | $116.00 | $107.18 | $113.12 | 8.78M |
| Aug 18, 2026 | $91.49 | $93.025 | $91.01 | $92.75 | 921.59K |
Latest BNTX news
The latest Smart Investors Daily articles mentioning BNTX.
Stock researchCompany · Overview
BNTX research
Overview
Company profile and research snapshot.
Company profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $144.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | BMO Capital | Market Perform | — |
| Aug 31, 2026 | Canaccord Genuity | Buy | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
| Jul 8, 2026 | Morgan Stanley | Overweight | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.